APP-FUBINACA

APP-FUBINACA is a synthetic cannabinoid that is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. It was originally developed by Pfizer in 2009 as an analgesic medication, but was not pursued for human use. Since 2012, APP-FUBINACA has been sold as an ingredient in synthetic cannabis products and as a research chemical.

Chemistry

APP-FUBINACA is an indazole-based synthetic cannabinoid. It is structurally related to other synthetic cannabinoids like AB-FUBINACA and ADB-FUBINACA. It has a molecular formula of C25H26FN3O and a molecular weight of 403.49 g/mol.

Pharmacology

APP-FUBINACA acts as a full agonist of the CB1 receptor and CB2 receptor, the primary molecular targets of the endocannabinoid anandamide. It has EC50 values of 0.52 nM and 0.88 nM respectively, indicating a high potency at these receptors.

Effects

The effects of APP-FUBINACA are similar to those of other synthetic cannabinoids and include euphoria, relaxation, and changes in perception. However, due to its high potency, it can also cause severe adverse effects such as psychosis, seizures, and cardiac arrest.

Legal status

APP-FUBINACA is a controlled substance in many countries, including the United States, where it is classified as a Schedule I drug under the Controlled Substances Act.

See also

• Synthetic cannabinoids
• Indazole
• CB1 receptor
• CB2 receptor

APP-FUBINACA Resources
Latest articles Most recent articles Ongoing trials	Wikipedia